925934-43-6

Basic information

• Product Name: (S)-{2-benzyloxy-1-[4-(2-tert-butyl-6-methoxy-8-quinolylamino)pentylcarbamoyl]ethyl}carbamic acid tert-butyl ester
• Synonyms: (S)-{2-benzyloxy-1-[4-(2-tert-butyl-6-methoxy-8-quinolylamino)pentylcarbamoyl]ethyl}carbamic acid tert-butyl ester
• CAS NO: 925934-43-6
• Molecular Weight: 592.779
• Mol File: 925934-43-6.mol
• Article Data: 1

Chemical Properties

• CAS DataBase Reference: (S)-{2-benzyloxy-1-[4-(2-tert-butyl-6-methoxy-8-quinolylamino)pentylcarbamoyl]ethyl}carbamic acid tert-butyl ester(CAS DataBase Reference)
• NIST Chemistry Reference: (S)-{2-benzyloxy-1-[4-(2-tert-butyl-6-methoxy-8-quinolylamino)pentylcarbamoyl]ethyl}carbamic acid tert-butyl ester(925934-43-6)
• EPA Substance Registry System: (S)-{2-benzyloxy-1-[4-(2-tert-butyl-6-methoxy-8-quinolylamino)pentylcarbamoyl]ethyl}carbamic acid tert-butyl ester(925934-43-6)

Safety Data

• Hazardous Substances Data: 925934-43-6(Hazardous Substances Data)

Upstream product

• 23680-31-1 BOC-O-benzyl-L-serine 
• 655250-09-2 N₈-(4-amino-1-methylpentyl)-2-tert-butyl-6-methoxy-8-quinolinamine 
• 85-81-4 6-methoxy-8-nitroquinoline 
• 655250-13-8 2-tert-butyl-6-methoxy-8-quinolinamine 
• 655250-11-6 2-tert-butyl-6-methoxy-8-nitroquinoline 
• 762301-51-9 2-[4-(2-tert-butyl-6-methoxy-8-quinolylamino)pentyl]-1,3-isoindolinedione 

Relevant articles and documents

Synthesis, antimalarial, antileishmanial, antimicrobial, cytotoxicity, and methemoglobin (MetHB) formation activities of new 8-quinolinamines

We report the synthesis, in vitro antiprotozoal (against Plasmodium and Leishmania), antimicrobial, cytotoxicity (Vero and MetHb-producing properties), and in vivo antimalarial activities of two series of 8-quinolinamines. N1-{4-[2-(tert-Butyl)-6-methoxy-8-quinolylamino]pentyl}-(2S/2R)-2-aminosubstitutedamides (21-33) and N1-[4-(4-ethyl-6-methoxy-5-pentyloxy-8-quinolylamino)pentyl]-(2S/2R)-2-aminosubstitutedamides (51-63) were synthesized in six steps from 6-methoxy-8-nitroquinoline and 4-methoxy-2-nitro-5-pentyloxyaniline, respectively. Several analogs displayed promising antimalarial activity in vitro against Plasmodium falciparum D6 (chloroquine-sensitive) and W2 (chloroquine-resistant) clones with high selectivity indices versus mammalian cells. The most promising analogs (21-24) also displayed potent antimalarial activity in vivo in a Plasmodium berghei-infected mouse model. Most interestingly, many analogs exhibited promising in vitro antileishmanial activity against Leishmania donovani promastigotes, and antimicrobial activities against a panel of pathogenic bacteria and fungi. Several analogs, notably 21-24, 26-32, and 60, showed less MetHb formation compared to primaquine indicating the potential of these compounds in 8-quinolinamine-based antimalarial drug development.